<a href="https://www.fiercebiotech.com/biotech/gsk-inks-106b-nuvalent-buyout-challenge-roche-and-pfizer-lung-cancer" hreflang="en">GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer</a>
GSK has agreed to acquire Nuvalent for $10.6 billion, aiming to enhance its lung cancer treatment portfolio with two near-approval therapies that could compete with offerings from Roche and Pfizer. The acquisition is seen as a strategic move to drive revenue growth and strengthen GSK's position in the oncology market amid upcoming challenges from generic competition.
GSK's $10.6 billion acquisition of Nuvalent provides a strategic entry into the lung cancer market, with potential "multiblockbuster" drugs zidesamtinib and neladalkib nearing FDA approval. For professionals tracking healthtech and biotech investments, this move signals GSK's commitment to expanding its oncology pipeline and highlights the lucrative potential of targeting niche cancer mutations, which could be a model for future M&A strategies in the sector.